The "OTO -Living Well with Dialysis" program launched globally on April 21, 2022 and will run until March 2023.

The "OTO" program aims to build a barrier-free communication bridge with international experts and doctors, share clinical experience, and improve precision medicine. It is a cooperation and exchange platform jointly initiated by the International Renal Research Institute of Vicenza, Renji Hospital of Shanghai Jiaotong University School of Medicine, and Zhongda Hospital of Southeast University. It will be run in 50 countries, serving nearly two hundred hospitals, including donation, round-table meetings, academic seminars, etc. In addition, more medical centers will be invited in the future.

At the launching ceremony, Prof. Claudio Ronco, Prof. Lu Renhua, and Prof. Zhang Xiaoliang, with extensive clinical experience, exchanged and shared the principles and knowledge of HA130 disposable hemoperfusion cartridges in the treatment of CKD complications as well as HA130 detection indicators, therapy frequency, and other related topics.

Chronic Kidney Disease (CKD) is a common type of kidney disease and a long-term medical condition in which the kidneys are injured and can't function. Kidney disease affects nearly 840 million people worldwide₁ and causes more than 1 million deaths each year₂. On the other hand, more than 9 million CKD patients progress to kidney failure, requiring dialysis or a kidney transplant₃. The disease affects up to 10% of the world's population₄. It is projected to become the fifth most common cause of death globally by 2040₅. Therefore, early detection and improved treatment options are urgently needed₆.

Based on evidence-based medicine in China, the "OTO -Living Well with Dialysis" program cooperates with the National Society of Nephrology to donate HA130 disposable hemoperfusion cartridges to hospitals worldwide. Jafron Biomedical sponsors hemoperfusion cartridges for the project. For example, each hospital will receive 40 clinical cartridges used for 8 HA130 hemoperfusion therapy for 5 patients. At the same time, Chinese and foreign experts are invited to conduct an in-depth exchange of experience, form a treatment SOP, and provide technical assistance and academic support to treat nephropathy and uremia in various countries.

Through joint efforts, Jafron tries to contribute to the global prevention and therapy development of chronic kidney disease. Overall, Jafron Biomedical will spare no effort to save lives, improve patients' quality of life, and realize the vision of "Health Technology for A Better World."

Reference:

1.         https://pubmed.ncbi.nlm.nih.gov/31582227/

2.         https://www.worldkidneyday.org/facts/chronic-kidney-disease/

3.         https://pubmed.ncbi.nlm.nih.gov/32061315/

4.         https://pubmed.ncbi.nlm.nih.gov/28434650/

5.         https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076785/

6.         https://www.astrazeneca.com/media-centre/articles/2021/putting-patient-perspectives-into-action-to-address-the-global-burden-of-chronic-kidney-disease.html